CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $18M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
233.91MEUR273.26M · vs all stocks (USD)
Revenue (TTM)
15.41MEUR18.00M · vs all stocks (USD)
Profit Margin
-15.76%vs Biotechnology peers
Beta
0.4400xvs all stocks
52-Week Change
1.21%vs all stocks
Market Capitalization
233.91MEUR273.26M · vs all stocks (USD)
Enterprise Value
212.23MEUR247.94M · vs all stocks (USD)
Forward P/E
317.11xvs Biotechnology peers
Price to Sales (TTM)
15.18xvs Biotechnology peers
Price to Book (MRQ)
1.85xvs Biotechnology peers
Enterprise to Revenue
13.78xvs Biotechnology peers
Enterprise to EBITDA
-36.33xvs Biotechnology peers
Profit Margin
-15.76%vs Biotechnology peers
Operating Margin
30.77%vs Biotechnology peers
Return on Assets (TTM)
-2.66%vs Biotechnology peers
Return on Equity (TTM)
-2.08%vs Biotechnology peers
Revenue (TTM)
15.41MEUR18.00M · vs all stocks (USD)
Revenue per Share (TTM)
0.1990EURUpdated Aug 22, 2026Quarterly Revenue Growth
106.00%vs Biotechnology peers
Gross Profit (TTM)
15.06MEUR17.60M · vs all stocks (USD)
EBITDA (TTM)
-5.84MEUR-6.82M · vs all stocks (USD)
Net Income (TTM)
-2.43MEUR-2.84M · vs all stocks (USD)
Operating Cash Flow (TTM)
-4.91MEUR-5.74M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-16.36MEUR-19.12M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00EURFY2025 · Dec 31, 2025Cost of Goods Sold
-10.65MEURFY2025 · Dec 31, 2025Gross Profit
10.65MEURFY2025 · Dec 31, 2025Operating Income
-5.71MEUR-6.67M · vs all stocks (USD)
Pre-tax Income
-5.60MEURFY2025 · Dec 31, 2025Income Tax Expense
-2.99MEURFY2025 · Dec 31, 2025Net Income
-2.61MEURFY2025 · Dec 31, 2025EBIT
-4.99MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-4.81MEURFY2025 · Dec 31, 2025Other Operating Expenses
12.42MEURFY2025 · Dec 31, 2025Non-operating Interest Income
713.27KEURFY2025 · Dec 31, 2025Non-operating Interest Expense
608.34KEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
-6.19MEURFY2025 · Dec 31, 2025Free Cash Flow
-6.25MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
28.35MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-5.60MEURFY2025 · Dec 31, 2025Other Non-cash Items
-79.93KEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-299.33KEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-215.76KEURFY2025 · Dec 31, 2025Capital Expenditures
-59.39KEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-10.98MEURFY2025 · Dec 31, 2025Purchase of Investments
0.00EURFY2025 · Dec 31, 2025Sale of Investments
1.86KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-57.54KEURFY2025 · Dec 31, 2025Long-term Debt Issuance
14.49MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-11.37MEURFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-4.69MEURFY2025 · Dec 31, 2025Common Stock Repurchase
0.00EURFY2025 · Dec 31, 2025Other Financing Charges
4.36MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
31.44MEURFY2025 · Dec 31, 2025Shares Outstanding
81.96MSharesUpdated Aug 22, 2026Float Shares
61.45MSharesUpdated Aug 22, 2026% Held by Insiders
20.15%vs all stocks
% Held by Institutions
0.94%vs all stocks
Total Cash (MRQ)
14.69MEUR17.16M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1890EURUpdated Aug 22, 2026Total Debt (MRQ)
10.80MEUR12.61M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0902xvs Biotechnology peers
Current Ratio (MRQ)
1.60xvs Biotechnology peers
Book Value per Share (MRQ)
1.54EURUpdated Aug 22, 2026Total Assets
144.52MEUR168.84M · vs all stocks (USD)
Total Current Assets
30.67MEURFY2025 · Dec 31, 2025Total Liabilities
26.68MEURFY2025 · Dec 31, 2025Total Non-current Assets
113.86MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
10.91MEURFY2025 · Dec 31, 2025Total Current Liabilities
15.77MEURFY2025 · Dec 31, 2025Cash
25.35MEURFY2025 · Dec 31, 2025Cash Equivalents
3.00MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
28.35MEURFY2025 · Dec 31, 2025Other Short-term Investments
14.58KEURFY2025 · Dec 31, 2025Accounts Receivable
106.57KEURFY2025 · Dec 31, 2025Inventory
3.73KEURFY2025 · Dec 31, 2025Accounts Payable
2.75MEURFY2025 · Dec 31, 2025Short-term Debt
4.55MEURFY2025 · Dec 31, 2025Long-term Debt
3.08MEURFY2025 · Dec 31, 2025Common Stock (Book)
3.99MEURFY2025 · Dec 31, 2025Retained Earnings
-20.81MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
117.85MEUR137.68M · vs all stocks (USD)
Treasury Stock
5.81MEURFY2025 · Dec 31, 202552-Week Low
2.60EURUpdated Aug 22, 202652-Week High
4.02EURUpdated Aug 22, 202652-Week Change
1.21%vs all stocks
Beta
0.4400xvs all stocks
50-Day MA
2.97EURUpdated Aug 22, 2026200-Day MA
3.01EURUpdated Aug 22, 2026Avg 10-Day Volume
187.06KSharesUpdated Aug 22, 2026Avg 30-Day Volume
241.93KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
-0.0300EURUpdated Aug 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.56
Altman Z-Score 5.16: safe zoneNotable
Altman Z-Score: 5.16
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $18M, lower than 95% of all stocks globallySignificant
Revenue (USD): 17,999,632.996Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sab Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Alx Oncology Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule